Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 HKD | 0.00% | +7.69% | -4.11% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.11% | 181M | |
-2.47% | 88.14B | |
+1.45% | 40.44B | |
-14.43% | 32.24B | |
+52.92% | 24.39B | |
-14.85% | 15.59B | |
-13.87% | 12.14B | |
-7.87% | 12.18B | |
-39.40% | 12.3B | |
+5.54% | 8.87B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Unit Ties Up with China Meheco Group Subsidiary to Distribute Ritonavir in Mainland China